A constitutively active STAT3 status is found in about 50–60% of breast tumors specifically in IBC after neoadjuvant chemotherapy [73], which is associated with tumorigenesis and drug resistance [74]. This evidence concerns the gene STAT3 and inflammatory breast carcinoma.